Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Melanoma | D008545 | — | — | 3 | 2 | 2 | — | — | 5 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 2 | 1 | — | — | 4 |
Carcinoma | D002277 | — | C80.0 | 3 | 2 | 1 | — | — | 4 |
Recurrence | D012008 | — | — | — | 1 | 2 | — | — | 2 |
Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | 1 | — | — | 2 |
Head and neck neoplasms | D006258 | — | — | — | 2 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 3 | 3 | — | — | — | 4 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | 3 | — | — | — | 3 |
Sarcoma | D012509 | — | — | 2 | 3 | — | — | — | 3 |
Prostatic neoplasms | D011471 | — | C61 | 2 | 1 | — | — | — | 2 |
Non-small-cell lung carcinoma | D002289 | — | — | 2 | 2 | — | — | — | 2 |
Triple negative breast neoplasms | D064726 | — | — | 2 | 2 | — | — | — | 2 |
Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | — | 2 |
Urologic neoplasms | D014571 | — | C64-C68 | 1 | 1 | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Covid-19 | D000086382 | — | — | 1 | — | — | — | — | 1 |
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | — | — | — | — | 1 |
Drug common name | Bempegaldesleukin |
INN | bempegaldesleukin |
Description | Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics.
|
Classification | Protein |
Drug class | interleukins: interleukin-2 analogues and derivatives; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1939126-74-5 |
RxCUI | — |
ChEMBL ID | CHEMBL4298058 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB15140 |
UNII ID | BNO1JG5MZC (ChemIDplus, GSRS) |